Global Multiple Vaccine Market Research Report 2024

Publication ID:

PB508242170

Publication Date:

August 19, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Multiple Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The process of upgrading global multi-vaccine products is a process of solidifying the competitive landscape.
This report aims to provide a comprehensive presentation of the global market for Multiple Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Vaccine.
Report Scope
The Multiple Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Segment by Type
Pentavalent Vaccine
Quadruple Vaccine
Triple Vaccine
Others
Segment by Application
Adult
Infants and Children
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Multiple Vaccine Market Overview
1.1 Product Overview and Scope of Multiple Vaccine
1.2 Multiple Vaccine Segment by Type
1.2.1 Global Multiple Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Pentavalent Vaccine
1.2.3 Quadruple Vaccine
1.2.4 Triple Vaccine
1.2.5 Others
1.3 Multiple Vaccine Segment by Application
1.3.1 Global Multiple Vaccine Market Value by Application: (2024-2030)
1.3.2 Adult
1.3.3 Infants and Children
1.4 Global Multiple Vaccine Market Size Estimates and Forecasts
1.4.1 Global Multiple Vaccine Revenue 2019-2030
1.4.2 Global Multiple Vaccine Sales 2019-2030
1.4.3 Global Multiple Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Multiple Vaccine Market Competition by Manufacturers
2.1 Global Multiple Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Multiple Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Multiple Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Multiple Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Vaccine, Product Type & Application
2.7 Multiple Vaccine Market Competitive Situation and Trends
2.7.1 Multiple Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Vaccine Players Market Share by Revenue
2.7.3 Global Multiple Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Vaccine Retrospective Market Scenario by Region
3.1 Global Multiple Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Multiple Vaccine Global Multiple Vaccine Sales by Region: 2019-2030
3.2.1 Global Multiple Vaccine Sales by Region: 2019-2024
3.2.2 Global Multiple Vaccine Sales by Region: 2025-2030
3.3 Global Multiple Vaccine Global Multiple Vaccine Revenue by Region: 2019-2030
3.3.1 Global Multiple Vaccine Revenue by Region: 2019-2024
3.3.2 Global Multiple Vaccine Revenue by Region: 2025-2030
3.4 North America Multiple Vaccine Market Facts & Figures by Country
3.4.1 North America Multiple Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Multiple Vaccine Sales by Country (2019-2030)
3.4.3 North America Multiple Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Multiple Vaccine Market Facts & Figures by Country
3.5.1 Europe Multiple Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Multiple Vaccine Sales by Country (2019-2030)
3.5.3 Europe Multiple Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Multiple Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Multiple Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Multiple Vaccine Market Facts & Figures by Country
3.7.1 Latin America Multiple Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Multiple Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Multiple Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Multiple Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Multiple Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Vaccine Sales by Type (2019-2030)
4.1.1 Global Multiple Vaccine Sales by Type (2019-2024)
4.1.2 Global Multiple Vaccine Sales by Type (2025-2030)
4.1.3 Global Multiple Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Multiple Vaccine Revenue by Type (2019-2030)
4.2.1 Global Multiple Vaccine Revenue by Type (2019-2024)
4.2.2 Global Multiple Vaccine Revenue by Type (2025-2030)
4.2.3 Global Multiple Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Multiple Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Multiple Vaccine Sales by Application (2019-2030)
5.1.1 Global Multiple Vaccine Sales by Application (2019-2024)
5.1.2 Global Multiple Vaccine Sales by Application (2025-2030)
5.1.3 Global Multiple Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Multiple Vaccine Revenue by Application (2019-2030)
5.2.1 Global Multiple Vaccine Revenue by Application (2019-2024)
5.2.2 Global Multiple Vaccine Revenue by Application (2025-2030)
5.2.3 Global Multiple Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Multiple Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Multiple Vaccine Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Multiple Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Mitsubishi Tanabe Pharma
6.3.1 Mitsubishi Tanabe Pharma Corporation Information
6.3.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.3.3 Mitsubishi Tanabe Pharma Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mitsubishi Tanabe Pharma Multiple Vaccine Product Portfolio
6.3.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.4 KM Biologics
6.4.1 KM Biologics Corporation Information
6.4.2 KM Biologics Description and Business Overview
6.4.3 KM Biologics Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 KM Biologics Multiple Vaccine Product Portfolio
6.4.5 KM Biologics Recent Developments/Updates
6.5 Wuhan Institute of Biological Products
6.5.1 Wuhan Institute of Biological Products Corporation Information
6.5.2 Wuhan Institute of Biological Products Description and Business Overview
6.5.3 Wuhan Institute of Biological Products Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Wuhan Institute of Biological Products Multiple Vaccine Product Portfolio
6.5.5 Wuhan Institute of Biological Products Recent Developments/Updates
6.6 Walvax Biotechnology
6.6.1 Walvax Biotechnology Corporation Information
6.6.2 Walvax Biotechnology Description and Business Overview
6.6.3 Walvax Biotechnology Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Walvax Biotechnology Multiple Vaccine Product Portfolio
6.6.5 Walvax Biotechnology Recent Developments/Updates
6.7 Chengdu Institute of Biological Products
6.6.1 Chengdu Institute of Biological Products Corporation Information
6.6.2 Chengdu Institute of Biological Products Description and Business Overview
6.6.3 Chengdu Institute of Biological Products Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chengdu Institute of Biological Products Multiple Vaccine Product Portfolio
6.7.5 Chengdu Institute of Biological Products Recent Developments/Updates
6.8 Minhai Biotechnology
6.8.1 Minhai Biotechnology Corporation Information
6.8.2 Minhai Biotechnology Description and Business Overview
6.8.3 Minhai Biotechnology Multiple Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Minhai Biotechnology Multiple Vaccine Product Portfolio
6.8.5 Minhai Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Vaccine Industry Chain Analysis
7.2 Multiple Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Vaccine Production Mode & Process
7.4 Multiple Vaccine Sales and Marketing
7.4.1 Multiple Vaccine Sales Channels
7.4.2 Multiple Vaccine Distributors
7.5 Multiple Vaccine Customers
8 Multiple Vaccine Market Dynamics
8.1 Multiple Vaccine Industry Trends
8.2 Multiple Vaccine Market Drivers
8.3 Multiple Vaccine Market Challenges
8.4 Multiple Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Sanofi
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂